Immuno-viral therapy as a new approach for the treatment of brain tumors

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The central nervous system (CNS) has been considered an immunologically privileged site; however, recent evidence suggests that activated T cells cross the intact blood-brain barrier and that a series of immunological events is initiated when T cells recognize CNS antigens. Therefore, brain tumors might be selectively eliminated by T cells activated with antigens specific for the tumors. Using a conditionally replicating herpes simplex virus-1 (HSV-1) mutant, G207, we developed a novel therapeutic approach for metastatic brain tumors that combines viral therapy with immunotherapy. G207 replicates selectively within tumor cells and causes tumor cell destruction without local or systemic toxicity, because its replication in normal cells is highly attenuated. Furthermore, the inoculation of tumors outside the CNS with G207 induces systemic immune responses not only to HSV but also to tumor antigens. In our strategy, in which both the metastatic brain tumor and the primary tumor outside the CNS are inoculated with G207, the HSV-infected brain tumor can be eliminated by the combined effects of the direct oncolysis and the induced anti-HSV and antitumor T cells. Recently, the safety of directly inoculating the human brain with G207 has been shown. These results indicate that our therapeutic approach using G207 may hold promise for the treatment of metastatic brain tumors.

Original languageEnglish
Pages (from-to)223-229
Number of pages7
JournalDrug News and Perspectives
Volume16
Issue number4
DOIs
Publication statusPublished - 2003 May

Fingerprint

Brain Neoplasms
T-Lymphocytes
Central Nervous System Neoplasms
Neoplasm Antigens
Central Nervous System
Therapeutics
Human Herpesvirus 1
Blood-Brain Barrier
Immunotherapy
Neoplasms
Safety
Antigens
Brain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Immuno-viral therapy as a new approach for the treatment of brain tumors. / Toda, Masahiro.

In: Drug News and Perspectives, Vol. 16, No. 4, 05.2003, p. 223-229.

Research output: Contribution to journalArticle

@article{5540991177a74c62ad91716a208afcf0,
title = "Immuno-viral therapy as a new approach for the treatment of brain tumors",
abstract = "The central nervous system (CNS) has been considered an immunologically privileged site; however, recent evidence suggests that activated T cells cross the intact blood-brain barrier and that a series of immunological events is initiated when T cells recognize CNS antigens. Therefore, brain tumors might be selectively eliminated by T cells activated with antigens specific for the tumors. Using a conditionally replicating herpes simplex virus-1 (HSV-1) mutant, G207, we developed a novel therapeutic approach for metastatic brain tumors that combines viral therapy with immunotherapy. G207 replicates selectively within tumor cells and causes tumor cell destruction without local or systemic toxicity, because its replication in normal cells is highly attenuated. Furthermore, the inoculation of tumors outside the CNS with G207 induces systemic immune responses not only to HSV but also to tumor antigens. In our strategy, in which both the metastatic brain tumor and the primary tumor outside the CNS are inoculated with G207, the HSV-infected brain tumor can be eliminated by the combined effects of the direct oncolysis and the induced anti-HSV and antitumor T cells. Recently, the safety of directly inoculating the human brain with G207 has been shown. These results indicate that our therapeutic approach using G207 may hold promise for the treatment of metastatic brain tumors.",
author = "Masahiro Toda",
year = "2003",
month = "5",
doi = "10.1358/dnp.2003.16.4.829334",
language = "English",
volume = "16",
pages = "223--229",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "4",

}

TY - JOUR

T1 - Immuno-viral therapy as a new approach for the treatment of brain tumors

AU - Toda, Masahiro

PY - 2003/5

Y1 - 2003/5

N2 - The central nervous system (CNS) has been considered an immunologically privileged site; however, recent evidence suggests that activated T cells cross the intact blood-brain barrier and that a series of immunological events is initiated when T cells recognize CNS antigens. Therefore, brain tumors might be selectively eliminated by T cells activated with antigens specific for the tumors. Using a conditionally replicating herpes simplex virus-1 (HSV-1) mutant, G207, we developed a novel therapeutic approach for metastatic brain tumors that combines viral therapy with immunotherapy. G207 replicates selectively within tumor cells and causes tumor cell destruction without local or systemic toxicity, because its replication in normal cells is highly attenuated. Furthermore, the inoculation of tumors outside the CNS with G207 induces systemic immune responses not only to HSV but also to tumor antigens. In our strategy, in which both the metastatic brain tumor and the primary tumor outside the CNS are inoculated with G207, the HSV-infected brain tumor can be eliminated by the combined effects of the direct oncolysis and the induced anti-HSV and antitumor T cells. Recently, the safety of directly inoculating the human brain with G207 has been shown. These results indicate that our therapeutic approach using G207 may hold promise for the treatment of metastatic brain tumors.

AB - The central nervous system (CNS) has been considered an immunologically privileged site; however, recent evidence suggests that activated T cells cross the intact blood-brain barrier and that a series of immunological events is initiated when T cells recognize CNS antigens. Therefore, brain tumors might be selectively eliminated by T cells activated with antigens specific for the tumors. Using a conditionally replicating herpes simplex virus-1 (HSV-1) mutant, G207, we developed a novel therapeutic approach for metastatic brain tumors that combines viral therapy with immunotherapy. G207 replicates selectively within tumor cells and causes tumor cell destruction without local or systemic toxicity, because its replication in normal cells is highly attenuated. Furthermore, the inoculation of tumors outside the CNS with G207 induces systemic immune responses not only to HSV but also to tumor antigens. In our strategy, in which both the metastatic brain tumor and the primary tumor outside the CNS are inoculated with G207, the HSV-infected brain tumor can be eliminated by the combined effects of the direct oncolysis and the induced anti-HSV and antitumor T cells. Recently, the safety of directly inoculating the human brain with G207 has been shown. These results indicate that our therapeutic approach using G207 may hold promise for the treatment of metastatic brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=0042433483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042433483&partnerID=8YFLogxK

U2 - 10.1358/dnp.2003.16.4.829334

DO - 10.1358/dnp.2003.16.4.829334

M3 - Article

C2 - 12942152

AN - SCOPUS:0042433483

VL - 16

SP - 223

EP - 229

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 4

ER -